Group B streptococcal epidemiology and vaccine needs in developed countries

Related Experiment Video

Updated: May 8, 2026

A Murine Model of Group B Streptococcus Vaginal Colonization
10:19

A Murine Model of Group B Streptococcus Vaginal Colonization

Published on: November 16, 2016

Pierrette Melin1, Androulla Efstratiou

  • 1National Reference Centre for Group B Streptococci, Medical Microbiology Department, University Hospital of Liege, Sart Tilman B-23, 4000 Liege, Belgium. Pierrette.Melin@chu.ulg.ac.be

Vaccine
|August 27, 2013
PubMed

Insights

Developing a group B streptococcal (GBS) vaccine is crucial for preventing infant infections, as current methods are insufficient. Genomics and new technologies are identifying promising universal GBS vaccine candidates.

Area of Science:

  • Microbiology
  • Vaccinology
  • Genomics

Background:

  • Group B Streptococcus (GBS) causes significant neonatal infections, with limited prevention strategies.
  • Intrapartum antibiotic prophylaxis has potential adverse effects and doesn't prevent all GBS disease types.
  • Existing GBS prevention methods are not fully effective for early-onset or late-onset disease.

Purpose of the Study:

  • To review the critical need for a GBS vaccine in developed countries.
  • To outline the current GBS epidemiology and microbiology relevant to vaccine development.
  • To highlight advancements in identifying universal GBS vaccine candidates.

Main Methods:

  • Review of current literature on GBS epidemiology and microbiology.
  • Analysis of genomic data and new technologies for vaccine candidate identification.
  • Assessment of existing GBS prevention strategies and their limitations.

Main Results:

  • Genomic approaches have identified novel vaccine candidates for GBS.
  • New technologies enable overcoming serotype limitations for a universal vaccine.
  • A GBS vaccine is of utmost importance due to the inadequacy of current prevention methods.

Conclusions:

  • A GBS vaccine is the most promising strategy to prevent GBS infections in infants.
  • Genomic insights and advanced technologies are key to developing effective GBS vaccines.
  • Further research is needed to address GBS epidemiology and develop a universal vaccine.

Keywords:
EpidemiologyGroup B streptococcusNeonatal infectionPreventionScreeningVaccine

More Related Videos

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens13:47

Opsono-Adherence Assay to Evaluate Functional Antibodies in Vaccine Development Against Bacillus anthracis and Other Encapsulated Pathogens

Published on: May 19, 2020

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/4306:06

Constructing Mutants in Serotype 1 Streptococcus pneumoniae strain 519/43

Published on: September 11, 2020

Related Concept Videos

Microorganisms in Medicine and Therapeutics01:29

Microorganisms in Medicine and Therapeutics

Microorganisms play a fundamental role in vaccine development, gene therapy, and therapeutic production. Their biological properties are harnessed to advance medicine and public health. Beyond immunization, microorganisms contribute to gut health, antibiotic synthesis, and genetic disease treatment.Live Attenuated and Inactivated VaccinesLive attenuated vaccines, such as the measles, mumps, and rubella (MMR) vaccine, utilize weakened forms of pathogens to closely resemble natural infections.
Vaccinations01:51

Vaccinations

Overview
Vaccine Production01:23

Vaccine Production

Vaccine production involves a sequence of upstream and downstream processes to generate a safe and effective immunological product. It begins with cultivating microorganisms, such as viruses or bacteria, to obtain antigenic material. For viral vaccines, mammalian host cells are grown in bioreactors and subsequently infected with the target virus. The virus replicates within the host cells, which are lysed to release viral particles. This lysate is then clarified through filtration or...
Infectious Diseases and Their Occurrence01:28

Infectious Diseases and Their Occurrence

Infectious diseases appear in populations through various transmission patterns, influenced by pathogen characteristics, population immunity, environmental conditions, and social behavior. Understanding these patterns is essential for effective public health surveillance and intervention. These categories—sporadic, outbreak, epidemic, pandemic, and endemic—help frame the nature and scope of disease events.Sporadic diseases occur irregularly and infrequently, without a predictable temporal or...
Bacterial Meningitis I: Introduction01:22

Bacterial Meningitis I: Introduction

Bacterial meningitis is a severe, life-threatening inflammation of the meninges, particularly the pia mater and arachnoid mater, affecting the subarachnoid space, ventricles, and cerebrospinal fluid (CSF). If untreated, it can lead to significant neurological complications or death.Causative AgentsCommon pathogens vary with age and immune status. In adults, major organisms include Streptococcus pneumoniae, Neisseria meningitidis, and Haemophilus influenzae. Streptococcus agalactiae (group B...
Clinical Significance of Antibiotic Resistance01:25

Clinical Significance of Antibiotic Resistance

Methicillin-resistant Staphylococcus aureus (MRSA) presents a critical public health threat, arising from its capacity to resist β-lactam antibiotics due to acquisition of the mecA gene within the staphylococcal cassette chromosome mec (SCCmec). This gene encodes penicillin-binding protein 2a (PBP2a), which impairs binding efficacy of methicillin and other β-lactams. MRSA has evolved into distinct clonal lineages impacting humans and animals alike, reinforcing its significance within the One...